# Structural and Functional Characterization of the Aorta in

2 Hypertrophic Obstructive Cardiomyopathy

- 3 AM. Ibrahim<sup>1,2</sup>, N. Latif<sup>3</sup>, M. Roshdy<sup>1</sup>, P. Sarathchandra<sup>3</sup>, M. Hosny<sup>1,4</sup>, A. Elsawy<sup>1</sup>, S.
- 4 Hekal<sup>1</sup>, A. Attia<sup>1</sup>, W. Elmozy<sup>1</sup>, A. Elaithy<sup>1</sup>, A. Elguindy<sup>1</sup>, A. Afifi<sup>1</sup>, Y. Aguib<sup>1,3\*</sup>, M.
- 5 Yacoub<sup>1,3\*</sup>

1

14

15

16

17

18

19

20

21

22

23

24

- 6 <sup>1</sup> Aswan Heart Center, Magdi Yacoub Heart Foundation, Aswan 200, Egypt
- <sup>2</sup> Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
- 8 <sup>3</sup> National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.
- 9 <sup>4</sup> Cardiology Department, Faculty of Medicine, Cairo University, Giza 11562, Egypt.
- 10 \*authors contributed equally
- 11 Corresponding authors: Ayman M. Ibrahim and Magdi Yacoub
- 12 E-mails: ayman.maher@aswanheartcentre.com and m.yacoub@imperial.ac.uk
- 13 Address: Aswan Heart Centre, Kasr ElHagar street, Aswan, Egypt

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Background and aims: Changes in the phenotype and genotype in Hypertrophic Obstructive Cardiomyopathy (HOCM) are thought to involve the myocardium as well as extracardiac tissues. The extent and significance of extra-myocardial changes has not been adequately studied. We here describe the structural and functional changes in the ascending aorta of HOCM patients. Methods: Changes in the aortic wall were studied in a cohort of 102 consecutive HOCM patients undergoing myectomy, and 10 normal controls. Biopsies were examined histologically, immunohistochemically and by electron microscopy. Changes in protein expression were quantified using morphometry and western blotting. Pulse wave velocity (PWV) was measured using Cardiac Magnetic Resonance (CMR), in 86 HCM patients compared to 166 age-matched normal controls. Results: In HCM, the number of medial lamellar units (MLU) was significantly decreased, associated with an increase in the interlamellar distance and a preserved thickness of the aortic wall, as compared to controls. Electron microscopy showed an altered lamellar structure with disorientation of elastin fibers from the circumferential direction. There was an altered composition and orientation of smooth muscle cells. In addition, there was a significant decrease in alpha-smooth muscle actin, smooth muscle myosin, smooth muscle 22 and integrin beta1, and a significant increase in calponin and caspase3. Fibulins 1, 2 and 5, had a reduced expression in HOCM aortic biopsies. Functionally, PWV was significantly higher in HOCM patients compared to healthy controls. Conclusion: In HOCM patients, specific molecular and structural changes in the composition and organisation of the arterial wall have been identified. This was associated with increased stiffness of the arterial wall.

**Keywords**: HCM, Aortic wall, lamellae, ECM, PWV

#### **Translational Perspective**

1

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

2 This study sheds light for the first time on the altered lamellar organization in

the aorta of Hypertrophic Obstructive Cardiomyopathy (HOCM), in addition to

the Smooth muscle cells and Extracellular Matrix abnormalities, to explain the

increased wall stiffness associated with patients clinical phenotype. The data

provide insights on extra-myocardial targets that can have potential value for

risk stratification and personalized therapeutics for HOCM patients.

#### Introduction

Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder affecting more than 1:500 in the general population <sup>1-3</sup>. HCM has always been defined with various myocardial changes and concentrating on disease-causing mutations related to sarcomeric genes 4-6. However, recent evidence has shown that HCM is heterogenous both at genotype and phenotype levels and involves many pathways and extra-myocardial tissues, such as the aorta <sup>7,8</sup>. Changes in the aortic stiffness have been reported in HCM 9,10 and correlated to exercise capacity 11. To date, the structural changes responsible for abnormalities in the aortic wall have not been studied. The wall of the aorta is highly elastic and dynamic which facilitates its function and response to the hemodynamic environment <sup>12–14</sup>. One of the major players that determine the arterial wall stiffness, and the physical properties of the aorta, is the medial elastic lamellar number and composition, which was first described by Glagov and colleagues <sup>15–17</sup>. This observation has since been the subject of many studies focusing on the medial lamellar unit (MLU) organization in physiological and pathological conditions <sup>18,19</sup>, which sometimes yielded contradictory results

due to the lack of adequate imaging techniques that can determine the 3D

structure of the MLU. A recent 3D modeling and imaging of MLU clarified their

exact composition and the functional interaction between the constituting

elements. <sup>19</sup>. The interlamellar space contains smooth muscle cells (SMCs) and

different extracellular matrix (ECM) components, which play a critical role in

determining the physical properties of the aortic wall, including stiffness <sup>20–23</sup>.

7 Elastin and collagen are the major components of the aortic wall ECM,

however, other matrix proteins such as fibrillin, fibulins (FBLNs), and matrix

metalloproteinases also play an important function in the aortic wall structure

10 <sup>21</sup>.

2

3

4

5

6

8

9

12

14

15

16

17

18

19

20

21

22

23

24

We here study in detail the number of elastic lamellae, and the width and

composition of the interlamellar space, particularly in relation to the changes in

13 ECM components as well as SMCs.

## Methods

# Patients samples

In all, 268 subjects were clinically examined (102 HCM and 166 controls [from

the ECCO-GEN study<sup>24</sup>](**Table 1** and **Supplementary data**). Written informed

consent was obtained from HCM patients and healthy subjects prior to their

inclusion in the study [(20130405MYFAHC\_CMR\_20130330) and

(20151125MYFAHC Hvol 20161027), respectively]. Control aortic biopsies

were acquired from the Magdi Yacoub Institute UK, upon a material transfer

agreement [Royal Brompton hospital ethics review board / Brompton and

Harefield trust ethics committee (REC approval 10/H0724/18)]. The study is

abiding by all the standards of the Declaration of Helsinki.

# Table 1: Clinical characteristics of Hypertrophic Cardiomyopathy (HCM) and Healthy volunteers [HVol] cohorts.

Clinical Parameters	HCM (n = 102)	Hvol (n=166)
Gender, Male n (%)	74 (72)	93 (56)
Age, years	39.4 ± 14.3	32.8 (25–36)
Body surface area BSA. m <sup>2</sup>	1.9 (1.71–2.1)	1.8 (1.7–2.0)
Body mass index	28.7 ± 6.2	26.4 (22.8–29.2)
<b>Dyspnea n (%)</b> New York Heart Association (NYHA) class	95 (93) Class I (n = 4) Class II (n = 31) Class III (n = 51) Class IV (n = 9)	0(0)
Angina n (%)	51 (0.5)	0(0)
Syncope	24(23)	0(0)
Max Septal wall thickness (cm)	2.4 (2– 2.8) *	NA
LVOTO resting gradient (mmHg)	103 (80–128)	NA
Left ventricular mass by CMR (gm)	204.5 (163.8–298.5) *	85.19 (62–106)
Left ventricular end systolic volume by CMR (ml)	19 (14–27) <sup>α</sup>	51.9 (39–61)
Left ventricular end diastolic volume by CMR (ml)	78 (67–93) <sup>α</sup>	134.58 (113–154)
Ejection Fraction% by CMR	74.9 ±8.21 <sup>α</sup>	63.4 (59–67)
Diastolic dysfunction n(%) Diastolic dysfunction Grade	102(100) Class 1 (n = 93) Class 2 (n = 7) Class 3 (n = 2)	0(0)
Cardiac Troponin I (ng/mL)	0.014 (0.009–0.03) <sup>¥</sup>	0.003 (0.0001–0.002) **

<sup>\*</sup>The data are available for 91 patients only,  $\alpha$  the data are available for 92 patients only,  $\xi$  the data are available for 75 patients only,  $\xi$  the data are available for 158 patients only,  $\xi$  the data are available for 86 patients only. Data are presented as mean  $\pm$  SD for normally distributed continuous variables, as median and interquartile range for non-normally distributed continuous variables, and as percentages (%) for categorical variables.

#### Tissue processing and histological staining

Thoracic aortic biopsies were collected, processed and prepared for staining as described before <sup>25</sup>. Briefly, for fibrous collagen staining, slides were incubated in picrosirius red stain (Abcam) for 1 hr and washed in 0.5% acetic acid for differentiation. Sections were dehydrated with increasing concentrations of ethanol, cleared with two changes of xylene (Sigma) and finally mounted with

- 1 DPX (Sigma). Slides were scanned and analyzed with a slide scanner (Zeiss-
- 2 Axioscan).

5

7

10

11

12

13

14

16

17

18

20

22

23

24

#### Immunohistochemistry and immunofluorescence

4 Section preparation was performed as described before <sup>25,26</sup>. All antibodies

were diluted using blocking solution; α-SMA 1:300 (Thermo Scientific™, # MS-

6 113-P, SMM 1:200 (Abcam, ab 133567), SM22 1:200 (abcam, ab14106)

calponin 1:200 (Dako, M3556), ITGβ1 1:150 (Abcam, #ab52971), Caspase3

8 1:50 (Abcam, #ab13847) FBLN2 1:200 (Thermo Scientific™, #PA5-21640),

9 FBLN1 1:200 (Thermo Scientific™, #MA5-24598) and FBLN5 1:200 (Thermo

Scientific™, #MA5-15395). Sections were incubated for 1 hr with HRP-goat

secondary antibody (Dako) and washed thrice prior to staining with DAB plus

Chromogen (Dako) for 1 min. For fluorescence reactions, washed sections

were incubated with secondary antibodies conjugated with fluorophores, (Goat

Anti-Mouse IgG H&L Alexa Fluor® 594) (abcam, ab150116) and (Goat Anti-

Rabbit IgG H&L Alexa Fluor® 488) (Abcam, #ab150077) at a 1:500 dilution,

incubated in the dark for 1 hr at RT, and then mounted with DAPI-containing

mounting media (Invitrogen™, Carlsbad, CA, USA, #P36962). The number of

lamellae and interlamellar distance were measured using Glagov's

19 methodology <sup>16,27</sup>.

#### Protein isolation and immunoblotting

21 Tissue biopsies were lysed and prepared for separation as described before

<sup>25,28</sup>. Briefly, 5 µg of protein per sample was separated and then transferred

from the SDS polyacrylamide gel onto Whatman® Protran® Nitrocellulose

Transfer Membrane (0.2 µm) (Sigma) using a Biorad transfer module, protein

transfer buffer (1X NuPage transfer buffer, 10% methanol in dH<sub>2</sub>O). The 1 membrane was incubated for 30 min at RT in 5% Marvel Original dried skimmed 2 3 milk blocking solution (in 1X PBS Tween-20 wash buffer). The membrane was then incubated for 2 hrs at RT with primary antibody (GAPDH (Cell Signaling, 4 2118S) at 1:500, FBLN2 at 1:1000, FBLN5 at 1:100 and FBLN1 at 1:1000), 5 washed thrice for 15 min, incubated for 1 hr at RT with horseradish peroxidase 6 7 (HRP)-labelled secondary antibody (Life Technologies) and washed thrice for 15 min. Reaction with HRP was carried out using ECL Western blotting 8 9 detection reagents (Life Technologies) and the signal was detected using an

#### Electron microscopy

Amersham Imager 600.

10

11

12

13

14

15

16

17

18

2 mm² samples were processed as described before <sup>29</sup>. Specimens were embedded in rubber molds, polymerised in the oven at 60°C. Ultra-thin sections (100nm) were collected on coated grids, post-stained with 2% aqueous Uranyl acetate and Reynolds lead citrate and viewed using JEOL 1200 transmission electron microscope. Digital micrographs were taken using a Gatan digital camera.

#### Pulse wave velocity

Cardiac magnetic resonance (CMR) was performed with a 1.5 T MRI machine

(Magnetom Aera - Siemens Healthineers, Erlanger, Germany). Pulse wave

velocity (PWV) was calculated using Segment software (Medviso AB, Lund,

Sweden), as per the formula; **PWV** =  $\Delta$  **D** /  $\Delta$ **T** (**m**/s), where  $\Delta$ D was the aortic

path length between the mid-aortic valve and mid-descending aorta, and  $\Delta$ T

- was the time delay between the arrival of the foot of the pulse wave at these
- 2 levels. (Supplementary methods and Supplementary Figure 1 and 2).

#### Results

3

4

232425

#### 1. The number and organization of MLU in HOCM aortic walls

- 5 The interlamellar distance was significantly increased in HCM aortic walls when
- 6 compared to controls, which was measured between two adjacent elastin fibres
- or two adjacent SMCs ( $\alpha$ -SMA+/ITG $\beta$ 1+) in the circumferential direction of the
- 8 fibres. Additionally, the number of lamellae was significantly reduced in HCM-
- 9 aortic walls. However, the overall thickness of the aortic wall remained
- unchanged in HOCM (Figure 1B and 1C).
- 11 Electron microscopy analysis of control aortic walls showed parallel
- 12 circumferential organisation of lamellae and SMCs, with tightly packed
- interlamellar collagen in wave like formation (Figure 1D- a, b and c). Elastin
- fibers were thick, continuous lamellar sheets, with interlamellar elastin fibers
- and radial rods <sup>19</sup>. At lower magnification, the HCM walls showed
- disorganisation of the lamellar unit associated with disorientation and/or
- fragmentation of a group of elastin sheets from the normal circumferential
- direction [(Figure 1D- a', red arrows) and (Figure 1D- b' asterix), respectively].
- 19 A moth-eaten appearance was also observed in a group of elastin sheets
- 20 (Figure 1D- b' and c'). The lamellar unit in HCM was sparsely packed at
- regions with ECM components compared to controls, with unoccupied spaces
- 22 and areas of randomly orientated collagen (Figure 1D- b'- c').

#### 2. Interlamellar space composition [SMCs and ECM]

#### 2.1. SMCs characteristics in HCM aorta

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

We next investigated the expression of markers pertaining to SMCs, the cell population occupying the MLU <sup>21</sup>. Immunohistochemical analyses showed a significant reduction in the expression of alpha-smooth muscle actin ( $\alpha$ -SMA), Smooth muscle myosin (SMM), calponin, smooth muscle 22 (SM22), and integrin beta-1 (ITGβ1), and a significant increase calponin expression in HCMaortic walls compared to controls (Figure 2A and supplementary Figure 3). To test whether the reduction in SMCs cells markers was associated with a depletion and/or apoptosis of SMCs, we assessed the expression of Caspase 3, as an apoptosis marker <sup>28</sup>, which showed a significantly increased expression in HCM-aortic walls compared to controls (Figure 2A). Electron microscopy imaging showed that SMCs in HCM samples contained fat globules, vacuoles, condensed nuclei, and irregular cell outlines, which is indicative of necrotic changes compared to control SMCs. Nonetheless, nuclei of SMCs in HCM appeared to remain intact (Figure 3).




Figure 1: Lamellar Organization in HCM aortic wall. A: Schematic diagram shows the medial elastic lamella organization in the aortic wall [adapted from El-Hamamsy and Yacoub, 2009, and O'Connell et al., 2008]. EL: elastin, ILE: interlamellar elastin, EL-s: elastin spurts, COL: collagen, SMC: smooth muscle cells, ECM: Extracellular Matrix, V: Vacuole and F: Fat globules. B: Confocal Microscopy shows the altered lamellar organization in HCM aortic walls, exhibited in the expression of SMA (green)

in contrast to elastin fibres (maron). White arrows point to the interlamellar distance.  $\bf C$ : Quantification of wall thickness, number of lamellae and the interlamellar distance in HCM (n=12) vs controls (n=3).  $\bf D$ : Electron micrographs of control (a, b and c) (n=3) and HCM (a', b' and c') (n=14) aortic walls. Asterix refers to radial elastin fragmentation a and a' (magnification 5K, bar=5  $\mu$ m), b and b' (magnification 12K, bar=2 $\mu$ m), c and c' (magnification 40K bar= 0.5 $\mu$ m).

# 2.2. ECM changes in HCM aorta - Collagen and Fibulins

1

2

4

5 6

7

8

9

10

11

12

13

14

15

16

17

18

19

20


21

22

23

24

Histopathological characterization of fibrous collagens in aortic wall tissues collected from HCM patients (n=102), showed a disorganization of collagen fibres compared to controls (n=10) (Figure 4A). Electron microscopy imaging of control collagen in transverse sections showed a minor variability in fibres diameter, however HCM samples showed a higher variability in collagen diameter and more loose fibres packing (Figure 4B- a and b). Similarly, longitudinal collagen fibres in control samples showed a minor variability in fibres thickness, whereas HCM samples had a group of thicker collagen strands with evident unravelling (Figure 4B- c and d, red arrow). In control aortic walls, ECM proteins, FBLN1, 2 and 5, were expressed in the elastin lamina in addition to the tunica media layer with a similar pattern to collagen and elastin fibres. In HCM-aortic walls, FBLN1 and FBLN2 expression was reduced, particularly in the tunica media, while FBLN5 was reduced across all wall layers, compared to controls (Figure 5A). Immunoblotting analysis confirmed the reduced expression of the three FBLNs in HCM-aortic lysates (Figure 5B and 5C).



**Figure 2: Expression of SMCs markers in HCM aortic wall.** Immunohistochemical staining of α-SMA, SMM, SM22, Calponin, ITGβ1 and caspase3 in HCM-aortic biopsies (n=102) compared to controls (n=10). Scale bars are 200 $\mu$ m and 50 $\mu$ m. Bar graphs show a significant decrease of α-SMA, SMM, SM22 and ITGB1, and a significant increase of calponin and caspase 3, in HCM-aortic biopsies compared to controls.


Control HCM

γ


2μm

2μm

Figure 3: SMCs abnormalities in HCM aortic wall. Electron micrographs of control (n=3) and HCM (n=14) aortic walls, showing the altered structure in SMCs in HCM walls. F: fat globules and V: vacuoles



**Figure 4: Collagen abnormalities in HCM aortic wall. A:** Picrosirius red staining in HCM aortic biopsies (n=102) compared to controls (n=10). Scale bars are 50μm. **B:** Electron micrographs of control (a and b) (n=3) and HCM (c and d) (n=14) aortic walls. Scale bar are 0.2μm. LS: longitudinal section. TS: Transverse section.



**Figure 5: ECM abnormalities in HCM aortic wall. A:** Immunohistochemical staining of FBLNs 1, 2 and 5 in HCM-aortic walls (n=102) compared to control walls (n=10). Scale bars are 200μm and 50μm. **B:** Immunoblot shows the reduction of total protein expression for FBLNs 1, 2 and 5 in HCM-aortic walls (n=6) compared to control walls (n=2). **C:** Quantification of FBLNs 1, 2 and 5 in HCM-aortic walls (n=6) compared to control walls (n=2).

**Discussion** 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

This study shows significant changes in the medial lamellar unit (MLU) of the aortic wall in HOCM patients, associated with increased wall stiffness. Recent evidence has shown that HCM is not entirely due to abnormalities in the sarcomere <sup>2,3,7</sup>. This notion has been supported by genome wide association studies (GWAS), which showed that HCM is linked to changes in genes involving many pathways in addition to the well-known variations in the sarcomeric genes <sup>7</sup>. One of the extracardiac manifestations of HCM is the altered stiffness of the aortic wall <sup>9,30–32</sup>, and the systemic increase of pro-fibrotic markers <sup>33,34</sup>. Aortic stiffness increases with age and is known to be an important prognostic indicator in patients with hypertension, atherosclerosis, and other diseases <sup>31,32,35</sup>. In addition, aortic stiffness has recently been shown to correlate to exercise capacity in HCM patients <sup>11</sup>. The current study confirms the increased stiffness of the aortic wall of HOCM patients, when compared to age-matched controls. To date, there have been no studies addressing the structural changes in the aortic wall of HOCM patients. Aortic Medial Lamellar Unit The lamellar unit of the aorta represents the active core that plays a major part in determining the physical characteristics of the aortic wall <sup>15,18</sup>. It was originally identified by Glagov and his colleagues, and has since been validated by many studies, that the number of the lamellae is related to the dimensions, tension, and pressure of the arteries 15-17,27. Recently, an advanced 3D modeling and

imaging of the MLU showed two dense layers of elastin constituting the

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

boundaries of the interlamellar space. The latter contains SMCs, oriented in a specific manner, as well as collagen fibres and other components of the ECM <sup>19</sup>. Our study documents for the first time a decrease in the number of elastic lamellae and an increase in the interlamellar distance and composition. This could influence the elasticity of the arterial wall and increase its stiffness. Electron microscopy and histological examination showed fragmentation in elastin sheets in HCM aortic walls. Elastin fibres confer compliance and recoil capacity to the aorta in response to mechanical stimuli 13,36. Elastin fragmentation is frequently observed in many aortopathies and has been shown to stimulate SMCs turnover <sup>23</sup>, which further agrees with our analysis that identified a significant reduction in the surface and contractile markers of SMCs. The interlamellar space in HOCM Apart from being wider in HOCM, the composition of the interlamellar space is altered. This is exemplified in the SMCs which showed changes in the orientation, shape, and size. These changes could possibly contribute to the increased stiffness by altering the vessel tone <sup>37,38</sup>. Our findings suggest that SMCs function could be further influenced by the reduction of ITGβ1 expression. ITGβ1 is a key signaling and mechanotransduction receptor of SMCs <sup>39</sup>. We further show a significant reduction in the SMC contractile proteins which suggests the dedifferentiation of SMCs to a migratory and proliferative phenotype and/or activation of apoptosis 40-42. This agrees with the increased expression of caspase3 in HCM aortic walls, an

observation that has been reported in many aortopathies, particularly aortic

aneurysm <sup>43,44</sup>. The significance and clinical relevance of these changes 1 2 requires further investigation. 3 This study also identified changes in the interlamellar space, represented in collagen and ECM proteins (FBLNs). Physiologically, collagen fibres, 4 particularly fibrous collagens I and III, provide tensile strength and overall 5 6 rigidity to the aorta 45,46. Our data showed disorganized collagen fibres in HOCM aortas, which can further contribute to wall stiffness. FBLNs expression was 7 reduced in HOCM aortic walls, particularly in the tunica intima and tunica media. 8 suggesting their contribution to the lamellar unit's conformation and function. 9 This was associated with a reduction in the basement membrane protein, 10 11 Collage IV (Supplementary Figure 4), which requires FBLN2 for proper assembly 47. FBLNs are a family of glycoproteins that have roles in ECM 12 remodeling, tropoelastin maturation and collagen fibre assembly 48-50. A notion 13 14 suggesting their relevance to the altered MLU. Structural and functional data presented in this study highlight the importance 15 of further unravelling the composition and role of the ECM and SMCs in the 16 human aorta in both physiological and pathological conditions, as it relates to 17 HOCM. 18 19 The limitation of this study is the fact that all studied patients had obstruction which could have influenced the results, however, the aortic biopsies were high 20 up in the ascending aorta and it's very unlikely to have been influenced by the 21 22 disturbed pattern of blood flow in the aortic root. In conclusion, these findings can be of special relevance to the management of 23 HOCM by identifying high-risk patients. In addition, it could provide new 24 therapeutic targets such as in the VANISH trial, which used Angiotensin-II 25

- receptor blocker-Valsartan that could be explained, at least in part, by the effect
- 2 of the drug on the arterial wall <sup>51</sup>.

# Funding

3

- 4 This study was supported by the Science and Technology Development Fund
- 5 (STDF) government grant (Egypt), Leducq Foundation (11 CVD-01) and
- 6 Aswan Heart Centre (Magdi Yacoub Heart Foundation). The views expressed
- 7 in this work are those of the authors and not necessarily those of the funders.

## **8 Conflict of interest**

9 The authors declare no conflict of interest.

# 10 Data availability statement

- All underlying data are available in the article and in its online supplementary
- 12 materials.

# 13 Acknowledgement

- The authors would like to thank Dr. Mona Allouba, Ms. Hadir Khedr, and Mr.
- Mohamed Elkhateb for their major contribution in acquiring the clinical data for
- 16 control healthy cohort.

#### References

17

- 19 1. Marian AJ. Update on hypertrophic cardiomyopathy. *Tex Heart Inst J* 2010;**37**:322–323.
- 21 2. Elliott P. Hypertrophic cardiomyopathy lifelong disease requiring lifelong treatment.
- 22 *Circulation* 2018;**138**:1399–1401.

- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2015;**65**:1249–1254.
- 3 4. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC,
- 4 Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F,
- 5 Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I. Genotype and Lifetime
- 6 Burden of Disease in Hypertrophic Cardiomyopathy. *Circulation* 2018;**138**:1387–1398.
- 7 5. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis,
- 8 Clinical Manifestations, Diagnosis, and Therapy. *Circ Res* 2017;**121**:749.
- 9 6. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Developmental origins of hypertrophic
- 10 cardiomyopathy phenotypes: A unifying hypothesis. *Nature Reviews Cardiology*.
- 11 7. Chou C, Chin MT. Pathogenic Mechanisms of Hypertrophic Cardiomyopathy beyond
- 12 Sarcomere Dysfunction. *Int J Mol Sci* 2021;**22**.
- 13 8. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to
- 14 Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the
- 15 Week. J Am Coll Cardiol 2019;**73**:1978–1986.
- 16 9. O'Rourke MF, Weber T, Adji A. Aortic Stiffness in Hypertrophic Cardiomyopathy. *J Am*
- 17 *Coll Cardiol* 2010;**55**:504–505.
- 18 10. Boonyasirinant T, Rajiah P, Setser RM, Lieber ML, Lever HM, Desai MY, Flamm SD.
- Aortic stiffness is increased in hypertrophic cardiomyopathy with myocardial fibrosis:
- 20 novel insights in vascular function from magnetic resonance imaging. J Am Coll
- 21 *Cardiol* 2009;**54**:255–262.
- 22 11. Austin BA, Popovic ZB, Kwon DH, Thamilarasan M, Boonyasirinant T, Flamm SD, Lever
- 23 HM, Desai MY. Aortic stiffness independently predicts exercise capacity in
- 24 hypertrophic cardiomyopathy: a multimodality imaging study. Heart 2010;96:1303–
- 25 1310.
- 26 12. Belz GG. Elastic properties and Windkessel function of the human aorta.
- 27 Cardiovascular Drugs and Therapy 1995 9:1 1995;**9**:73–83.
- 28 13. Akhtar R, Sherratt MJ, Cruickshank JK, Derby B. Characterizing the elastic properties
- 29 of tissues. *Materials Today* 2011;**14**:96–105.
- 30 14. Lin CJ, Staiculescu MC, Hawes JZ, Cocciolone AJ, Hunkins BM, Roth RA, Lin CY,
- 31 Mecham RP, Wagenseil JE. Heterogeneous Cellular Contributions to Elastic Laminae
- Formation in Arterial Wall Development. *Circ Res* 2019;**125**:1006–1018.
- 33 15. Wolinsky H, Glagov S. A Lamellar Unit of Aortic Medial Structure and Function in
- 34 Mammals. *Circ Res* 1967;**20**:99–111.
- 35 16. Glagov S, Ko C, Bassiouny HS, Zarins CK. Principles of Vascular Remodeling. *Pan*
- 36 *Vascular Medicine* 2002:232–241.
- 37 17. Zatina MA, Zarins CK, Gewertz BL, Glagov S. Role of medial lamellar architecture in
- the pathogenesis of aortic aneurysms. *J Vasc Surg* 1984;**1**:442–448.

- 1 18. Taghizadeh H, Tafazzoli-Shadpour M. Characterization of mechanical properties of
- 2 lamellar structure of the aortic wall: Effect of aging. J Mech Behav Biomed Mater
- 3 2017;**65**:20–28.
- 4 19. O'Connell MK, Murthy S, Phan S, Xu C, Buchanan JA, Spilker R, Dalman RL, Zarins CK,
- 5 Denk W, Taylor CA. The Three-Dimensional Micro- and Nanostructure of the Aortic
- 6 Medial Lamellar Unit Measured Using 3D Confocal & Electron Microscopy Imaging.
- 7 *Matrix Biol* 2008;**27**:171.
- 8 20. Qasem A, Avolio A. Determination of aortic pulse wave velocity from waveform
- decomposition of the central aortic pressure pulse. *Hypertension* 2008;**51**:188–195.
- 10 21. El-Hamamsy I, Yacoub MH. Cellular and molecular mechanisms of thoracic aortic
- 11 aneurysms. *Nat Rev Cardiol* 2009;**6**:771–786.
- 12 22. Phillippi JA, Green BR, Eskay MA, Kotlarczyk MP, Hill MR, Robertson AM, Watkins SC,
- 13 Vorp DA, Gleason TG. Mechanism of aortic medial matrix remodeling is distinct in
- 14 patients with bicuspid aortic valve Evolving Technology/Basic Science Phillippi et al
- 15 ET/BS. 2014.
- 16 23. Jana S, Hu M, Shen M, Kassiri Z. Extracellular matrix, regional heterogeneity of the
- 17 aorta, and aortic aneurysm. Experimental & Molecular Medicine 2019 51:12
- 18 2019;**51**:1–15.
- 19 24. Aguib Y, Allouba M, Afify A, Halawa S, El-Khatib M, Sous M, Galal A, Abdelrahman E,
- 20 Shehata N, Sawy A El, Elmaghawry M, Anwer S, Kamel O, Mozy W El, Khedr H,
- 21 Kharabish A, Thabet N, Theotokis PI, Buchan R, Govind R, Whiffin N, Walsh R, Aguib
- 22 H, Elguindy A, O'Regan DP, Cook SA, Barton PJ, Ware JS, Yacoub M. The Egyptian
- 23 Collaborative Cardiac Genomics (ECCO-GEN) Project: defining a healthy volunteer
- 24 cohort. npj Genomic Medicine 2020 5:1 2020;**5**:1–8.
- 25. Ibrahim AM, Roshdy M, Elshorbagy S, Hosny M, Halawa S, Yehia D, Elfawy HA,
- 26 Eldessouki A, Mohamed F, Ellithy A, Abdelfattah M, Elsawy A, Elkhatib M, Allouba M,
- 27 Elguindy A, Aguib Y, Yacoub M. An Investigation of Fibulin-2 in Hypertrophic
- 28 Cardiomyopathy. *Int J Mol Sci* 2020;**21**:1–14.
- 29 26. Kindi HN Al, Shehata M, Ibrahim AM, Roshdy M, Simry W, Aguib Y, Yacoub MH. Cor
- 30 Triatriatum sinister (Divided Left Atrium): histopathological features and clinical
- 31 management. *Ann Thorac Surg* 2020.
- 32 27. Xu C, Zarins CK, Glagov S. Aneurysmal and occlusive atherosclerosis of the human
- 33 abdominal aorta. *J Vasc Surg* 2001;**33**:91–96.
- 34 28. Kindi HN Al, Ibrahim AM, Roshdy M, Abdelghany BS, Yehia D, Masoud AN, Simry W,
- 35 Aguib Y, Yacoub MH. Clinical, cellular, and molecular characterisation of cardiac
- rhabdomyoma in tuberous sclerosis. *Cardiol Young* 2021;**31**:1297–1305.
- 37 29. Tseng Y-T, Grace NF, Aguib H, Sarathchandra P, McCormack A, Ebeid A, Shehata N,
- 38 Nagy M, El-Nashar H, Yacoub MH, Chester A, Latif N. Biocompatibility and Application
- 39 of Carbon Fibers in Heart Valve Tissue Engineering. Front Cardiovasc Med 2021;8.
- 40 30. Angoff R, Mosarla RC, Tsao CW. Aortic Stiffness: Epidemiology, Risk Factors, and
- 41 Relevant Biomarkers. Front Cardiovasc Med 2021;8.

- 1 31. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness.
- 2 *Hypertension* 2005;**45**:1050–1055.
- 3 32. Saeed S, Saeed N, Grigoryan K, Chowienczyk P, Chambers JB, Rajani R. Determinants
- 4 and clinical significance of aortic stiffness in patients with moderate or severe aortic
- 5 stenosis. *Int J Cardiol* 2020;**315**:99–104.
- 6 33. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC,
- 7 Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F,
- 8 Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I. Genotype and Lifetime
- 9 Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric
- Human Cardiomyopathy Registry (SHaRe). *Circulation* 2018;**138**:1387–1398.
- 11 34. Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R,
- 12 González A, Colan SD, Seidman JG, Díez J, Seidman CE. Myocardial Fibrosis as an Early
- 13 Manifestation of Hypertrophic Cardiomyopathy A bs tr ac t. N Engl J Med
- 14 2010;**363**:552–563.
- 15 35. McNulty M, Mahmud A, Spiers P, Feely J. Collagen type-I degradation is related to
- arterial stiffness in hypertensive and normotensive subjects. *J Hum Hypertens*
- 17 2006;**20**:867–873.
- 18 36. Yanagisawa H, Wagenseil J. Elastic fibers and biomechanics of the aorta: Insights from
- mouse studies. *Matrix Biol* 2020;**85–86**:160–172.
- 20 37. Durgin BG, Straub AC. Redox control of vascular smooth muscle cell function and
- 21 plasticity. *Laboratory Investigation* 2018;**98**:1254–1262.
- 22 38. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis.
- 23 *Cardiovasc Res* 2012;**95**:156–164.
- 24 39. Humphrey JD, Schwartz MA, Tellides G, Milewicz DM. Role of Mechanotransduction
- 25 in Vascular Biology. *Circ Res* 2015;**116**:1448–1461.
- 26 40. Latif N, Sarathchandra P, McCormack A, Yacoub MH, Chester AH. Atypical Expression
- of Smooth Muscle Markers and Co-activators and Their Regulation in Rheumatic
- 28 Aortic and Calcified Bicuspid Valves. Front Cardiovasc Med 2022;9:587.
- 29 41. Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth
- 30 muscle cell fate and plasticity in atherosclerosis. *Cardiovasc Res* 2018;**114**:540–550.
- 31 42. Beamish JA, He P, Kottke-Marchant K, Marchant RE. Molecular Regulation of
- 32 Contractile Smooth Muscle Cell Phenotype: Implications for Vascular Tissue
- 33 Engineering. *Tissue Eng Part B Rev* 2010;**16**:467.
- 34 43. Rowe VL, Stevens SL, Reddick TT, Freeman MB, Donnell R, Carroll RC, Goldman MH.
- 35 Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human
- 36 aortas. *J Vasc Surg* 2000;**31**:567–576.
- 37 44. Thompson RW, Liao S, Curci JA. Vascular smooth muscle cell apoptosis in abdominal
- aortic aneurysms. *Coron Artery Dis* 1997;**8**:623–631.

1 45. Pichamuthu JE, Phillippi JA, Cleary DA, Chew DW, Hempel J, Vorp DA, Gleason TG. 2 Differential tensile strength and collagen composition in ascending aortic aneurysms 3 by aortic valve phenotype. Ann Thorac Surg 2013;96:2147–2154. 4 Rest M Van Der, Garrone R. Collagen family of proteins. The FASEB Journal 46. 1991;5:2814-2823. 5 6 47. Ibrahim AM, Sabet S, El-Ghor AA, Kamel N, Anis SE, Morris JS, Stein T. Fibulin-2 is 7 required for basement membrane integrity of mammary epithelium. Scientific 8 Reports 2018 8:1 2018;8:1-14. 9 48. Timpl R, Sasaki T, Kostka G, Chu M-L. Fibulins: a versatile family of extracellular matrix 10 proteins. Nat Rev Mol Cell Biol 2003;4:479-489. 11 49. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: Physiological and 12 disease perspectives. EMBO Rep 2003;4:1127-1131. 13 50. Olijnyk D, Ibrahim AM, Ferrier RK, Tsuda T, Chu ML, Gusterson BA, Stein T, Morris JS. 14 Fibulin-2 is involved in early extracellular matrix development of the outgrowing 15 mouse mammary epithelium. Cell Mol Life Sci 2014;71:3811-3828. 16 51. Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, 17 18 Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, Krieger JE, Sacilotto L, 19 20 Arteaga E, Antunes MO, Hall EK, Choudhury L, Pahl E, Lin KY, Lewis GD, Desai AS, Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Valsartan 21 22 in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 23 2021;**27**:1818-1824. 24 25 26 27 28 29 30 31 32 33